<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="148099">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02030587</url>
  </required_header>
  <id_info>
    <org_study_id>CRE-2012.193-T</org_study_id>
    <nct_id>NCT02030587</nct_id>
  </id_info>
  <brief_title>Laparoscopic Adrenalectomy Versus Radiofrequency Ablation</brief_title>
  <acronym>LARFA</acronym>
  <official_title>Laparoscopic Adrenalectomy Versus Radiofrequency Ablation for Aldosterone-producing Adenoma: a Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <authority>Hong Kong: Joint CUHK-NTEC Clinical Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomized controlled study comparing laparoscopic adrenalectomy (LA)
      versus image-guided percutaneous radiofrequency ablation (RFA) in treating
      aldosterone-producing adenoma.

      The objectives of this study are to

        1. compare the short-term outcomes of LA and RFA in treating aldosterone-producing
           adenoma.

        2. compare the treatment success rates of LA and RFA during follow-up for primary
           aldosteronism.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Morbidity rate</measure>
    <time_frame>30-day</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Resolution of hyperaldosteronism</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Operative time</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Periprocedural hypertensive crisis</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood loss</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic requirement</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resumption of activity</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of hypokalaemia</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure control</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Hyperaldosteronism</condition>
  <condition>Conn Syndrome</condition>
  <condition>Adrenocortical Adenoma</condition>
  <arm_group>
    <arm_group_label>Radiofrequency Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiofrequency Ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laparoscopic Adrenalectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Laparoscopic Adrenalectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiofrequency Ablation</intervention_name>
    <arm_group_label>Radiofrequency Ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic Adrenalectomy</intervention_name>
    <arm_group_label>Laparoscopic Adrenalectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Hypertensive individuals

          2. Biochemically confirmed primary aldosteronism

          3. Radiologically confirmed unilateral adrenal adenoma â‰¤3cm

        Exclusion Criteria:

          1. Bilateral adrenal disease

          2. Multiple adrenal tumors

          3. Other concomitant adrenal diseases

          4. Potentially malignant adrenal tumors as shown on imaging

          5. Uncorrected coagulopathy

          6. Surgically unfit for general anaesthesia

          7. Prior open abdominal surgery
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enders KW Ng, MB ChB</last_name>
    <role>Study Chair</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shirley YW Liu, MB ChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shirley YW Liu, MB ChB</last_name>
    <phone>+852 26322956</phone>
    <email>liuyw@surgery.cuhk.edu.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirley YW Liu, MB ChB</last_name>
      <phone>+852 26322956</phone>
      <email>liuyw@surgery.cuhk.edu.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <reference>
    <citation>Liu SY, Ng EK, Lee PS, Wong SK, Chiu PW, Mui WL, So WY, Chow FC. Radiofrequency ablation for benign aldosterone-producing adenoma: a scarless technique to an old disease. Ann Surg. 2010 Dec;252(6):1058-64. doi: 10.1097/SLA.0b013e318f66936.</citation>
    <PMID>21107117</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 7, 2014</lastchanged_date>
  <firstreceived_date>January 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Enders K.W. Ng</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hyperaldosteronism</keyword>
  <keyword>Adrenocortical adenoma</keyword>
  <keyword>Adrenalectomy</keyword>
  <keyword>Catheter ablation</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Hyperaldosteronism</mesh_term>
    <mesh_term>Adrenocortical Adenoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
